Magnesium Glycinate Benefits, Backed by Studies

TL;DR

Magnesium glycinate has one placebo-controlled trial on its own form, and it found a small improvement in insomnia severity. Its clearest advantage over other forms is tolerability. Most of what gets claimed for magnesium generally comes from trials in people who were low in magnesium to begin with, and the effect often shrinks or disappears in people who already have enough. The cramp claim, which appears on nearly every magnesium page, fails at the Cochrane level.

What magnesium glycinate is

Magnesium glycinate is magnesium bound to two molecules of glycine. Its precise name is magnesium bisglycinate, and both names describe the same compound.

Magnesium itself is the second most abundant positively charged ion inside your cells, and it takes part in more than 600 enzymatic reactions, including energy metabolism and protein synthesis. It matters most visibly in the brain, heart, and skeletal muscle (de Baaij 2015).

The distinction that changes how you read every claim

Two different questions get answered by magnesium research, and they get treated as one.

The first is whether magnesium does something in people who are short of it. The second is whether taking more helps someone whose intake is already adequate. Most magnesium trials recruit the first group, and most benefits pages report the results as though they answer the second question.

The evidence for that pattern is direct rather than theoretical. A meta-analysis of 38 blood pressure trials in 2,709 people found an overall systolic reduction of 2.81 mm Hg. In people with hypomagnesemia the reduction reached 5.97 mm Hg, and in people on blood pressure medication it reached 7.68 mm Hg. Among people with normal blood pressure, the result did not reach statistical significance (Argeros 2025).

The same shape appears in a trial where the researchers looked. In 100 adults over 51 with poor sleep, magnesium raised serum magnesium only in the 37 participants whose levels were below the deficiency threshold at baseline. Across the whole group, it did not move at all (Nielsen 2010).

Working out which group you fall into is harder than it should be. Reviewers have noted the absence of standardized tests for assessing magnesium status (Schuchardt and Hahn 2017), and serum magnesium is a blunt instrument, as the Nielsen trial shows. Dietary intake is a rough proxy. In that same trial, food diaries put 58 percent of participants below the US Estimated Average Requirement.

Sleep

One placebo-controlled trial has tested magnesium bisglycinate specifically.

It enrolled 155 adults aged 18 to 65 with self-reported poor sleep and gave them 250 mg of elemental magnesium as bisglycinate or placebo. Insomnia Severity Index scores fell further on magnesium than placebo at four weeks, -3.9 against -2.3 (p = 0.049). The effect size was small, Cohen's d of 0.2, which the authors called a modest benefit. Exploratory analysis found the improvement concentrated among participants with lower baseline dietary magnesium intake, which the authors flagged as a possible high-responder subgroup (Schuster 2025). One author runs a contract research organization funded by supplement companies.

That is the whole of the form-specific sleep evidence. Everything else was collected with other forms.

A trial in 46 older adults with primary insomnia gave 500 mg of magnesium daily for eight weeks. Insomnia severity scores fell, sleep time and sleep efficiency rose, and sleep onset latency shortened (Abbasi 2012). A meta-analysis pooling three trials in 151 older adults found sleep onset latency 17.4 minutes shorter than placebo, and rated all three trials at moderate to high risk of bias with evidence quality low to very low (Mah and Pitre 2021).

The most instructive sleep trial found nothing. Researchers gave 320 mg of magnesium citrate or placebo to 100 adults over 51 with poor sleep for seven weeks. Sleep quality improved substantially in both groups, from a Pittsburgh score of 10.4 down to 6.6, with no difference between magnesium and placebo. The authors concluded that something else, possibly a placebo effect, drove the improvement, and that this prevented them from determining whether magnesium status affects sleep at all (Nielsen 2010).

Read together: a small real effect on insomnia severity from the glycinate form, a larger apparent effect in older adults where the evidence is weak, and a well-run trial where placebo did the same work. Magnesium is worth trying for sleep, provided you expect a modest nudge rather than a sedative.

Anxiety and stress

A systematic review of 18 studies concluded the evidence suggests a benefit of magnesium on subjective anxiety. Every study it reviewed recruited people who were already vulnerable, whether mildly anxious, premenstrual, postpartum, or hypertensive. The reviewers rated the quality of the existing evidence as poor and called for properly designed trials (Boyle 2017).

That recruitment pattern carries the weight here. The anxiety evidence describes people who were already anxious, already low in magnesium, or both.

The largest stress trial recruited 264 healthy adults with high stress scores and serum magnesium in the low range, and gave them 300 mg daily. Stress scores fell by more than 40 percent over eight weeks (Pouteau 2018). The design compared magnesium against magnesium plus vitamin B6, with no placebo arm, so it cannot separate the supplement from the passage of time. Take the size of that drop with that in mind.

Tolerability, the clearest glycinate advantage

This is where the glycinate form has the most defensible claim.

A double-blind crossover study gave magnesium diglycinate and magnesium oxide to 12 patients who had undergone ileal resection, tracking absorption with a labeled isotope. Absorption across the whole group came out similar, 23.5 percent for the chelate against 22.8 percent for the oxide. In the four patients whose absorption was most impaired, the chelate did much better. It peaked in the blood earlier, and every patient tolerated it better than the oxide. The authors concluded that part of the magnesium diglycinate is likely absorbed intact through a dipeptide transport route rather than the usual mineral pathway (Schuette 1994).

Twelve patients with surgically shortened bowels is a narrow base for a general claim, and it remains the most direct evidence on the point.

The reason tolerability matters is that loose stools set the ceiling on magnesium dosing. The US upper intake level for supplemental magnesium was set at 350 mg a day with diarrhea as the limiting factor, though a 2023 review argued the newer data support raising it, since most trials between 128 and 1,200 mg daily found no difference in diarrhea against placebo (Costello 2023). A form you can take at a useful dose without disruption is worth more than a form with a marginally better absorption number on paper.

Worth keeping in perspective: a review of the absorption literature concluded the type of magnesium salt matters less than dose, dose timing, and existing magnesium status (Schuchardt and Hahn 2017).

Where general magnesium evidence holds up

These results came from trials using other magnesium forms. None of them tested glycinate.

Blood pressure. The 38-trial meta-analysis above found meaningful reductions in people with hypertension or hypomagnesemia, and no statistically significant effect in people with normal blood pressure. Heterogeneity across studies was high and no dose-response relationship emerged (Argeros 2025).

Blood sugar. A double-blind trial gave 382 mg of magnesium as magnesium chloride, or placebo, to 116 adults with both prediabetes and hypomagnesaemia for four months. Fasting glucose, post-load glucose, HOMA-IR, and triglycerides all improved against placebo, and half the magnesium group improved their glucose category against 7 percent on placebo (Guerrero-Romero 2015). Note the entry criteria. Everyone in that trial was both prediabetic and low in magnesium.

Migraine. A dose-response meta-analysis of 22 supplement trials found magnesium reduced migraine attack frequency (mean difference -2.51), severity (-0.88), and monthly migraine days (-1.66) (Talandashti 2025). A Cochrane review on this question was registered in 2025, and at the time of writing only the protocol has been published, so no Cochrane verdict exists yet.

The cramp claim does not hold up

Magnesium is marketed for muscle cramps almost universally. Cochrane looked at it across 11 trials in 735 people.

For older adults with idiopathic cramps, the most common presentation, magnesium performed no better than placebo on any measure. The change in cramps per week came to -9.59 percent with a confidence interval crossing zero, and the proportion of people getting at least a 25 percent reduction in cramp rate was flat between groups, a relative risk of 1.04 rated high-certainty evidence. Cramp intensity and duration showed nothing either. The reviewers concluded it is unlikely magnesium provides clinically meaningful cramp prevention for older adults. For pregnancy-associated leg cramps the literature is conflicting and the trials are at high risk of bias (Garrison 2020).

The same review found more minor adverse events on magnesium than placebo, mostly gastrointestinal.

If muscle relaxation is the reason you're considering magnesium, this is the honest answer, and it argues for glycinate on tolerability rather than on cramp relief.

How much, and when

Trials that showed sleep effects used between 250 and 500 mg of elemental magnesium daily (Schuster 2025, Abbasi 2012). The supplemental upper level sits at 350 mg with diarrhea as the reason (Costello 2023).

Check the elemental figure on the supplement facts panel rather than the compound weight on the front of the bottle. The two numbers differ by a lot.

Splitting the dose through the day rather than taking it all at once tends to improve both absorption and tolerance (Schuchardt and Hahn 2017).

The bisglycinate sleep trial ran four weeks before measuring, and the older-adult insomnia trial ran eight. Give it weeks.

For the form comparison, see magnesium glycinate vs citrate and magnesium bisglycinate vs glycinate. For the brain-targeted form, see magnesium L-threonate benefits. For the decision page across all forms, see which magnesium is best for sleep and anxiety. On the glycine half of the molecule, see glycine for sleep.

FAQ

What does magnesium glycinate actually do?

It delivers magnesium, which participates in more than 600 enzymatic reactions and matters for nerve and muscle function (de Baaij 2015). The glycinate part makes it easier on the gut than oxide (Schuette 1994). On outcomes you would notice, one placebo-controlled trial found a small reduction in insomnia severity (Schuster 2025).

Is it good for sleep and anxiety?

For sleep, modestly, with a small effect size in the one bisglycinate trial and better results in people whose dietary magnesium was low (Schuster 2025). For anxiety, the reviewed evidence is suggestive and rated poor quality, and every study recruited people already vulnerable to anxiety (Boyle 2017).

How long does it take to work?

The bisglycinate trial measured its main result at four weeks (Schuster 2025). The insomnia trial in older adults ran eight weeks (Abbasi 2012). Judge it after a month, not after three nights.

What's the best time to take it?

Evening, if sleep is your reason, since that's when the trials dosed it. Splitting the total across the day suits absorption better (Schuchardt and Hahn 2017), so a split with the larger portion at night is a reasonable compromise.

Will it stop my leg cramps?

Probably not. Cochrane found no meaningful benefit for idiopathic cramps in older adults, with the responder analysis rated high-certainty (Garrison 2020).

Do I need it if my diet is decent?

That's the right question and it's hard to answer, since standardized tests for magnesium status are lacking (Schuchardt and Hahn 2017) and serum magnesium misses most of what's happening inside cells. The pattern across trials is that people who start low gain more. In the bisglycinate sleep trial, lower baseline dietary magnesium predicted a bigger response (Schuster 2025).

Disclaimer

This article is for general information only. It is not medical advice and it does not replace guidance from a qualified healthcare professional. Magnesium supplements can interact with certain medications, including some antibiotics, bisphosphonates, and diuretics. People with reduced kidney function should not take supplemental magnesium without medical supervision, because impaired kidneys cannot clear excess magnesium. Do not use this information to diagnose or treat any condition. Speak with your doctor before starting any supplement.